The Centers for Disease Control and Prevention (CDC) Division of HIV Prevention tracks outbreaks, provides education and establishes guidelines for the United States and the world, according to Terri L. Wilder, MSW, HIV/Aging Policy Advocate at SAGE, an organization that serves LGBTQ+ elders.
The Centers for Disease Control and Prevention (CDC) Division of HIV Prevention may be in trouble, according to today’s announcement from the U.S. Department of Health and Human Services stating the Trump administration will cut approximately 10,000 jobs under the HHS. The change comes as part of President Trump's Executive Order, “Implementing the President’s ‘Department of Government Efficiency’ Workforce Optimization Initiative.”
Terri L. Wilder, MSW, an HIV/aging policy advocate at the elder LGBTQ+ organization SAGE, spoke with Managed Healthcare Executive and shared why the CDC’s Division of HIV Prevention is an important resource.
“The CDC is really important to public health in the United States and quite frankly, the world, because the world looks to the CDC for guidance,” Wilder said. “The CDC creates the HIV screening guidelines available to healthcare providers to guide them in how to offer HIV testing to the patients that come into their practice. [The CDC] exports these policies. It's not just people in the United States that are healthcare providers that go to the CDC website. It's healthcare and public health providers around the world, because the CDC is a trusted source of information.”
Approximately 1.2 million people are living with HIV in the United States, and an estimated 13% don’t know they have it, according to the CDC. Cases have fallen 12% from 2018 to 2022, in which 31,800 new cases were reported.
Funding and restructuring rumors began to swirl last week, thanks to an article published by the Wall Street Journal. The article reported that the HHS had been debating whether to drastically cut funding.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More